My only critique is in this part. My guess is that pretreatment antibiotics are likely always going to be needed/superior, so a better future study would be to have a comparison of FMT with bacteria producing beneficial compounds vs ones that don’t/just take up space.

I’m especially intrigued by this part as it opens the door to a new target/mechanism for those designing the FMT strains - namely, improving a patient’s stool through boosting what they already have. That seems more durable to me given high rates of recolonization/return to baseline.

I think part of it is that our main academic site had a quality initiative around it a few years ago. Between the procedure teams and eager residents, it usually gets taken care of within 12 hours.

I haven't seen any data for gaining back more weight after stopping. In general, the effects wear off over time, like they do for most medications. The long that patients are on it/the more weight they lose, the longer the benefit lasts.

Yeah, we would notice a large rise in myocarditis. Weird (and tired) take.